LON:STX - Shield Therapeutics Stock Price, Price Target & More Sign in or create an account to add this stock to your watchlist. Get Started GBX 39.50 0.00 (0.00 %) (As of 07/15/2018 04:00 PM ET)Previous CloseGBX 39.50Today's RangeGBX 39.50 - GBX 39.5052-Week RangeGBX 15 - GBX 168.50VolumeN/AAverage Volume48,665 shsMarket Capitalization£20.52 millionP/E RatioN/ADividend YieldN/ABetaN/A Company ProfileAnalyst RatingsHeadlinesChart Share on FacebookShare on TwitterShare on LinkedInShare on RedditShare on StocktwitsPrint this articleShare by Email Shield Therapeutics plc, a specialty pharmaceutical company, focuses on the development and commercialization of secondary care-focused pharmaceuticals. Its lead product is Feraccru, a novel therapy for the treatment of iron deficiency anemia in patients with inflammatory bowel disease. Its advanced pipeline asset is PT20, a novel therapy that has completed its first pivotal study for the treatment of hyperphosphatemia in patients with chronic kidney disease. The company also develops PT30 and PT40 intravenous iron formulations. Shield Therapeutics plc was founded in 2008 and is based in Gateshead, the United Kingdom. Receive STX News and Ratings via Email Sign-up to receive the latest news and ratings for STX and its competitors with MarketBeat's FREE daily newsletter. Industry, Sector and Symbol Stock Exchange LON Industry Drug Manufacturers - Specialty & Generic Sub-IndustryN/A SectorMedical SymbolLON:STX CUSIPN/A Webwww.shieldtherapeutics.com Phone+44-191-5118500 Debt Debt-to-Equity RatioN/A Current RatioN/A Quick RatioN/A Price-To-Earnings Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / CashN/A Book ValueN/A Price / BookN/A Profitability EPS (Most Recent Fiscal Year)N/A Net IncomeN/A Net Margins-6,780.28% Return on Equity-38.71% Return on Assets-36.22% Miscellaneous EmployeesN/A Outstanding Shares116,430,000Market Cap£20.52 Shield Therapeutics (LON:STX) Frequently Asked Questions What is Shield Therapeutics' stock symbol? Shield Therapeutics trades on the London Stock Exchange (LON) under the ticker symbol "STX." What price target have analysts set for STX? 1 brokers have issued 1-year price objectives for Shield Therapeutics' shares. Their forecasts range from GBX 220 to GBX 265. On average, they anticipate Shield Therapeutics' share price to reach GBX 243.33 in the next year. This suggests a possible upside of 516.0% from the stock's current price. View Analyst Ratings for Shield Therapeutics. What is the consensus analysts' recommendation for Shield Therapeutics? 1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Shield Therapeutics in the last year. There are currently 1 buy rating for the stock, resulting in a consensus recommendation of "Buy." Who are some of Shield Therapeutics' key competitors? Some companies that are related to Shield Therapeutics include Cipher Pharmaceuticals (CPHRF), Marijuana Company Of America (MCOA), Amryt Pharma (AMYT), Acerus Pharmaceuticals (ASP), Indiva (NDVA), Science in Sport (SIS), CV Sciences (CVSI), Aequus Pharmaceuticals (AQS), EVIO (EVIO), Evgen Pharma (EVG), Venture Life Group (VLG), ESSA Pharma (EPI), Mountain High Acquisitions (MYHI), Lattice Biologics (LBL) and Premier Biomedical (BIEI). Who are Shield Therapeutics' key executives? Shield Therapeutics' management team includes the folowing people: Mr. Carl Sterritt, Co-Founder, CEO & Director (Age 50)Dr. Karl Keegan BSc, MPhil, Ph.D., MSc, Interim Chief Financial Officer (Age 51)Fleur Wood, Director of Investor RelationsMs. Suzanne Wood, Group HR DirectorMr. Paul Steckler, Chief Commercial Officer Has Shield Therapeutics been receiving favorable news coverage? News coverage about STX stock has been trending somewhat positive this week, according to Accern Sentiment Analysis. The research firm ranks the sentiment of media coverage by reviewing more than 20 million news and blog sources. Accern ranks coverage of public companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Shield Therapeutics earned a media sentiment score of 0.09 on Accern's scale. They also gave press coverage about the company an impact score of 46.41 out of 100, indicating that recent media coverage is somewhat unlikely to have an effect on the company's share price in the immediate future. How do I buy shares of Shield Therapeutics? Shares of STX and other U.K. stocks can be purchased through online brokerage accounts that support trading on the London Stock Exchange (LSX). Some U.K. companies can be purchased through major U.S. brokerages in the form of American Depository Receipts (ADRs), which are placeholder equities held in a trust by a bank that represent shares of a foreign stock. What is Shield Therapeutics' stock price today? One share of STX stock can currently be purchased for approximately GBX 39.50. How big of a company is Shield Therapeutics? Shield Therapeutics has a market capitalization of £20.52 million. How can I contact Shield Therapeutics? Shield Therapeutics' mailing address is 3rd Fl Baltic Business Quarters, Abbott's Hill, GATESHEAD, NE8 3D, United Kingdom. The company can be reached via phone at +44-191-5118500. MarketBeat Community Rating for Shield Therapeutics (LON STX)Community Ranking: 2.8 out of 5 ( )Outperform Votes: 107 (Vote Outperform)Underperform Votes: 82 (Vote Underperform)Total Votes: 189MarketBeat's community ratings are surveys of what our community members think about Shield Therapeutics and other stocks. Vote "Outperform" if you believe STX will outperform the S&P 500 over the long term. Vote "Underperform" if you believe STX will underperform the S&P 500 over the long term. You may vote once every thirty days. This page was last updated on 7/15/2018 by MarketBeat.com StaffFeatured Article: What are CEFs?